AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Study 2019: Includes Historic Industry Data from 2016 and Forecasts to 2026 - ResearchAndMarkets.com

November 20, 2019

DUBLIN--(BUSINESS WIRE)--Nov 20, 2019--

The “Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment” report has been added to ResearchAndMarkets.com’s offering.

The Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment market is expected to reach $34.1 billion by 2026 growing at a CAGR of 7.7% during the forecast period.

Increasing awareness regarding neuro-developmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth. However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Based on the Age Group, the Adults segment is estimated to have a lucrative growth due to the high prevalence of the condition across the globe, increased awareness about mental health, and launch of effective drugs with minimum adverse effects.

The key vendors mentioned are Alcobra, Amarantus, Curemark, Eli Lilly and Company, Highland Therapeutics, Johnson & Johnson Services, LLC, Lupin, Mallinckrodt, Medice, NEOS Therapeutics Inc., Neurovance, Nextwave Pharmaceuticals, Novartis AG, Noven Pharmaceuticals, Pfizer, Prude Pharma L.P., Recordati, Rhodes Pharmaceuticals, Shionogi, and Shire.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Drug

5.1 Introduction

5.2 Amphetamine

5.3 Atomoxetine

5.4 Bupropion

5.5 Clonidine

5.6 Dexmethylphenidate

5.7 Guanfacine

5.8 Lisdexamfetamine

5.9 Methylphenidate

5.10 Dextroamphetamine

6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Type

6.1 Introduction

6.2 Non-Stimulants

6.3 Stimulants

7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Age Group

7.1 Introduction

7.2 Adult (Aged 18 and above)

7.3 Children (2-17 years of age)

7.4 Pediatric and Adolescent

8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Distribution Channel

8.1 Introduction

8.2 E-Commerce

8.3 Hospital Pharmacy

8.4 Retail Pharmacy

8.5 Specialty Clinics

9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Geography

9.1 North America

9.2 Europe

9.3 Asia-Pacific

9.4 South America

9.5 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape

11.1 Alcobra

11.2 Amarantus

11.3 Curemark

11.4 Eli Lilly & Company

11.5 Highland Therapeutics

11.6 Johnson & Johnson Services, LLC

11.7 Lupin

11.8 Mallinckrodt

11.9 Medice

11.10 NEOS Therapeutics Inc.

11.11 Neurovance

11.12 Nextwave Pharmaceuticals

11.13 Novartis AG

11.14 Noven Pharmaceuticals

11.15 Pfizer

11.16 Prude Pharma L.P.

11.17 Recordati

11.18 Rhodes Pharmaceuticals

11.19 Shionogi

11.20 Shire

For more information about this report visit https://www.researchandmarkets.com/r/83gh97

View source version on businesswire.com:https://www.businesswire.com/news/home/20191120005811/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/20/2019 01:17 PM/DISC: 11/20/2019 01:16 PM

http://www.businesswire.com/news/home/20191120005811/en